Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis (Nasdaq: ZNTL) announced that an abstract reporting results from Part 1 of the Phase 1b MUIR trial of azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC) was accepted for presentation at the ASCO 2026 Annual Meeting on June 1, 2026.
The poster (Abstract 5529, Poster Board 195) will be presented during the Gynecologic Cancer poster session from 9:00–12:00 CDT and highlights combinability and activity of the regimen in an all-comer setting.
Zentalis (Nasdaq: ZNTL) will present preclinical and real-world data at AACR 2026 on azenosertib, a WEE1 inhibitor. Preclinical TNBC models showed antitumor activity (42–99% TGI) and 7/8 complete responses in an ADC-resistant PDX with azenosertib+enfortumab vedotin. Real-world ovarian cancer data show Cyclin E1-positive patients have shorter time to next treatment (13.2/14.9 vs 19.5 months; p=0.002).
The posters detail combination strategies in TNBC and unmet need in Cyclin E1-positive ovarian cancer relevant to ongoing DENALI and ASPENOVA programs.
Zentalis (Nasdaq: ZNTL) selected 400mg QD 5:2 azenosertib monotherapy as the pivotal dose for Cyclin E1-positive platinum-resistant ovarian cancer based on a prespecified DENALI Part 2a interim analysis.
The company reported a clearly differentiated response rate at 400mg versus 300mg with comparable safety, no treatment-related deaths, plans to include Part 2a data in the full Part 2 dataset, will initiate Part 2c enrollment in Q2 2026, and expects a DENALI Part 2 topline readout by year-end 2026.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on April 1, 2026 that its Compensation Committee granted non-qualified stock options for an aggregate of 36,000 shares to two newly hired employees under the 2022 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).
The options carry a $2.57 exercise price (closing price on the grant date), a 10-year term, and four-year vesting (25% after one year, remainder monthly over three years), subject to continued service.
Zentalis (Nasdaq: ZNTL) reported full-year 2025 results and clinical progress on azonosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. Cash, cash equivalents and marketable securities totaled $245.9 million as of December 31, 2025, with runway projected into late 2027.
Key 2026 milestones include DENALI Part 2a dose confirmation in 1H 2026, DENALI Part 2 topline readout by year-end 2026, and initiation of Phase 3 ASPENOVA in 1H 2026; MUIR Part 2 combination study is ongoing.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) will present two scientific posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. One poster reports preclinical data on azenosertib combination strategies for Triple-Negative Breast Cancer; the other reports real-world Cyclin E1 biomarker findings in ovarian cancer.
Poster details include presentation dates, times, abstract numbers, and presenters; posters will be posted on the company Supporting Publications page when presented.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced management participation in three investor conferences in late February and March 2026. The schedule includes virtual and in-person fireside discussions at Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 9).
According to the company, live webcasts and archived recordings will be available for at least 30 days under the Investors & Media "Events & Presentations" tab.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11, 2026 at 3:30 p.m. ET in New York. A live webcast and archived recording will be available under the company's Investors & Media "Events & Presentations" tab for at least 30 days.
Zentalis (Nasdaq: ZNTL) provided a corporate update on January 6, 2026 outlining 2026 milestones for azenosertib, its investigational WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key points: DENALI Part 2a enrollment completed with dose confirmation expected in 1H 2026, DENALI Part 2 topline readout expected by year-end 2026 (could support accelerated approval, subject to FDA feedback), and initiation of the randomized Phase 3 ASPENOVA trial planned in 1H 2026. The company reported $280.7M cash and equivalents as of Sept 30, 2025, providing an estimated runway into late 2027.
Zentalis (Nasdaq: ZNTL) reported third quarter 2025 results and operational updates on Nov 10, 2025. The company has $280.7 million in cash, cash equivalents and marketable securities, which it says provides runway into late 2027. The Phase 2 DENALI trial of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer remains on track with topline data from Part 2 expected by year-end 2026 and potential to support accelerated approval, subject to FDA feedback. Enrollment completed in the TETON Phase 2 uterine serous carcinoma trial; results are planned for publication in first half 2026. Quarterly operating expenses declined to $33.7M.